Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate of lorvotuzumab linked to mertansine intended for CD56 positive cancers (e.g. small-cell lung cancer ovarian cancer).It has been granted Orphan drug status for Merkel cell carcinoma.It has reported encouraging Phase II results for small-cell lung cancer.
This page contains content from the copyrighted Wikipedia article "Lorvotuzumab mertansine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
